the result of univariate analysis showed that PD-L1 TPS expression, MLR, PLT, whether receiving immunotherapy, and age were significant prognostic factors affecting OS in NSCLC patients after receiving first-line EGFR-TKIs therapy resistance (p<0.05) (Table 3), while gender, smoking history, EGFR driver mutation type, ECOG score, NEUT, LYM, MON, NLR, and PLR had no significant effect on OS of the patients. Here, EGFR is linked to non-small cell lung carcinoma.